<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02045693</url>
  </required_header>
  <id_info>
    <org_study_id>AI443-108</org_study_id>
    <nct_id>NCT02045693</nct_id>
  </id_info>
  <brief_title>Drug Interaction &amp; Methadone &amp; Buprenorphine</brief_title>
  <official_title>A Phase1, Open-Label, Drug-Drug Interaction Study Between Methadone and Daclatasvir/Asunaprevir/BMS-791325 3 DAA FDC + 75mg BMS-791325 and Between Buprenorphine/Naloxone and Daclatasvir/Asunaprevir/BMS-791325 3 DAA FDC +75mg BMS-791325</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of steady state DCV/ASV/BMS-791325 fixed
      dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of Methadone in
      subjects with the stable dose of Methadone and on the PK of Buprenorphine in subjects with
      the stable dose of Buprenorphine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IND number: 101,943

      Primary purpose: Other: Phase 1 Clinical Pharmacology drug interaction study in healthy
      subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of R-Methadone for Part 1</measure>
    <time_frame>24 timepoints up to Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC(TAU)) of R-Methadone for Part 1</measure>
    <time_frame>24 timepoints up to Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Buprenorphine and Norbuprenorphine for Part 2</measure>
    <time_frame>24 timepoints up to Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(TAU) of Buprenorphine and Norbuprenorphine for Part 2</measure>
    <time_frame>24 timepoints up to Day 13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of S-Methadone and Total Methadone for Part 1</measure>
    <time_frame>24 timepoints up to 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(TAU) of S-Methadone and Total Methadone for Part 1</measure>
    <time_frame>24 timepoints up to 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 24 hours (C24) of S-Methadone, Total Methadone and R-Methadone for Part 1</measure>
    <time_frame>24 timepoints up to 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax) of S-Methadone, Total Methadone and R-Methadone for Part 1</measure>
    <time_frame>24 timepoints up to 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C24 of Buprenorphine and Norbuprenorphine for Part 2</measure>
    <time_frame>24 timepoints up to 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Buprenorphine and Norbuprenorphine for Part 2</measure>
    <time_frame>24 timepoints up to 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(TAU) to parent AUC(TAU) (MR_AUC(TAU)) of Norbuprenorphine to Buprenorphine</measure>
    <time_frame>24 timepoints up to 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of of Daclatasvir (DCV) , Asunaprevir (ASV) , BMS-791325, and BMS-794712</measure>
    <time_frame>10 timepoints on Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(TAU) of DCV, ASV, BMS-791325, and BMS-794712</measure>
    <time_frame>10 timepoints on Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 12 hours (C12) of DCV, ASV, BMS-791325, and BMS-794712</measure>
    <time_frame>10 timepoints on Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of DCV, ASV, BMS-791325, and BMS-794712</measure>
    <time_frame>10 timepoints on Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR_AUC(TAU) for BMS-794712 to BMS-791325</measure>
    <time_frame>10 timepoints on Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), death and AEs leading to discontinuation</measure>
    <time_frame>Up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of vital signs, Electrocardiograms (ECGs), Physical Examinations (PEs) and clinical labs</measure>
    <time_frame>Up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores of Clinical Opiate Withdrawal Scale (COWS), Subjective Opiate Withdrawal Scale (SOWS), Objective Opiate Withdrawal Scale (OOWS), and Opiate Overdose Assessment (OOA)</measure>
    <time_frame>Up to day 13</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Part 1: Methadone + DCV 3DAA FDC + BMS-791325</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methadone 40-120 mg tablet or solution orally once on Day 1
Methadone 40-120 mg tablet or solution orally once daily + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3 direct-acting antiviral (3DAA) fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once on Day 1
Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3DAA fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <arm_group_label>Part 1: Methadone + DCV 3DAA FDC + BMS-791325</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCV 3DAA FDC</intervention_name>
    <arm_group_label>Part 1: Methadone + DCV 3DAA FDC + BMS-791325</arm_group_label>
    <arm_group_label>Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-791325</intervention_name>
    <arm_group_label>Part 1: Methadone + DCV 3DAA FDC + BMS-791325</arm_group_label>
    <arm_group_label>Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <arm_group_label>Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <arm_group_label>Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Subject must be on stable Methadone or Buprenorphine regimens for at least 28 days
             prior to screening

        Exclusion Criteria:

          -  Subjects must be healthy except for history of Methadone or Buprenorphine treatment
             regimens

          -  Prior exposure to DCV, ASV or BMS-791325 within 3 months of screening or any other
             investigational drug or placebo within 4 weeks of study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials Llc</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cri Lifetree</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2014</study_first_posted>
  <last_update_submitted>June 16, 2014</last_update_submitted>
  <last_update_submitted_qc>June 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

